Cancer Advisor

Medical Reviewed | Updated for 2026 Clinical Insights Quick Summary: While chemotherapy remains a lifesaving cornerstone of oncology, emerging peer-reviewed research indicates that in specific clinical scenarios, cytotoxic treatments can inadvertently alter the surrounding tissue microenvironment. This alteration can sometimes trigger the reactivation of dormant cancer cells or facilitate metastasis (the spread of cancer to other parts of the body). Understanding these mechanisms allows modern oncology to develop targeted strategies that neutralize these risks while preserving treatment efficacy. Introduction: The Paradox of Cancer Care Despite trillions of dollars invested in oncology research globally, cancer remains a leading cause of mortality, claiming roughly 10 million lives annually. Data published in The Lancet indicates that the global incidence of major malignancies—including breast, lung, and col...

Nothing in this article constitutes medical advice. The science discussed is published, peer-reviewed research. Its application to any individual’s treatment decisions requires a qualified clinician who can assess their specific circumstances and baseline hematological parameters. Lisa’s Carcinoembryonic Antigen ( CEA ) marker had plummeted from 1,500 down to 3.6. Let that quantitative metric sit for a moment. A tumor marker that had been catastrophically elevated—the kind of baseline number that forces oncology teams to choose their words with extreme care—had returned to a completely normal physiological reference range within four months. Her dominant hepatic lesions had been mechanically destroyed by histotripsy , a non-thermal, non-ionizing intervention that utilizes focused ultrasound waves to induce acoustic cavitation. Her surgical team recognized the structural success. Her metabolic protocol was running exactly as designed. Read More ...

For decades, chemotherapy was the backbone of cancer treatment. While chemotherapy can still save lives, a major shift is happening in oncology: immunotherapy is increasingly replacing — or dramatically reducing — the need for chemotherapy in selected cancers. Checkpoint inhibitors, CAR-T therapies, bispecific antibodies, tumor vaccines and precision immunotherapy combinations are changing survival outcomes once considered impossible. In some cancers, chemotherapy-free treatment is already becoming a new standard of care. Here are 10 cancers where immunotherapy is reshaping the future of treatment. 1. Melanoma Few cancers demonstrate the power of immunotherapy better than melanoma. Before checkpoint inhibitors, metastatic melanoma had extremely poor survival rates. Today, drugs targeting PD-1 and CTLA-4 have transformed outcomes for many patients. Examples include: Pembrolizumab Nivolumab Ipilimumab In many advanced melanoma cases: Immunotherapy is preferred before chemotherapy Durable...

Abstract Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by aggressive biology, late diagnosis, and limited therapeutic options. Despite advances in multi-agent chemotherapy, the prognosis for metastatic disease remains poor. This review synthesizes current evidence on standard-of-care regimens, including NALIRIFOX and FOLFIRINOX, emerging targeted and immunotherapeutic approaches, and explores the potential repurposing of antiparasitic agents such as fenbendazole and ivermectin. We discuss recent clinical trials, safety profiles, and future directions for improving outcomes in stage 4 PDAC. Pancreatic Cancer Awareness Introduction Pancreatic cancer is among the most aggressive and therapeutically challenging malignancies, with a 5-year survival rate below 10% for all stages combined. Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC) , which are frequently diagnosed at an advanced stage, limiting cura...